The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 179, 2467 -2476
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turcotte, K.
Right arrow Articles by Gros, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turcotte, K.
Right arrow Articles by Gros, P.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Malaria
*Salmonella Infections
*Tuberculosis

Icsbp1/IRF-8 Is Required for Innate and Adaptive Immune Responses against Intracellular Pathogens1

Karine Turcotte*,{dagger}, Susan Gauthier*, Danielle Malo{dagger},{ddagger},§, Mifong Tam{dagger}, Mary M. Stevenson{dagger} and Philippe Gros2,*,{dagger}

* Department of Biochemistry, {dagger} Centre for the Study of Host Resistance, {ddagger} Department of Medicine, and § Department of Human Genetics, McGill University, Montreal, Quebec, Canada


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The chronic myeloid leukemia syndrome of the BXH-2 mouse strain (Mus musculus) is caused by a recessive mutation (R294C) in the transcriptional regulator Icsbp1/IRF-8. In trans activation assays using an IL-12p40 gene reporter construct introduced in RAW 264.7 mouse macrophages, we show that the Icsbp1C294 isoform behaves as a partial loss-of-function. The Icsbp1C294 hypomorph allele appears to have a threshold effect on IL-12 production, with pleiotropic consequences on resistance to different types of infections in vivo. Despite the presence of a resistance Nramp1G169 allele, BXH-2 mice (Icsbp1C294) show impaired control of Mycobacterium bovis (bacille Calmette-Guérin) multiplication both early and late during infection, with uncontrolled replication linked to inability to form granulomas in infected liver and spleen. Studies in informative (BXH-2 x BALB/cJ)F2 mice show that homozygosity for Icsbp1C294 causes susceptibility to Salmonella enterica serovar Typhimurium to a level comparable to that seen for mice lacking functional Nramp1 or TLR4. Finally, impaired Icsbp1C294 function is associated with the following: 1) increased replication of the Plasmodium chabaudi AS malarial parasite during the first burst of blood parasitemia, and 2) recurring waves of high blood parasitemia late during infection. These results show that Icsbp1 is required for orchestrating early innate responses and also long-term immune protection against unrelated intracellular pathogens.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Nramp1 (Slc11a1) plays a critical role in macrophage defenses against intracellular pathogens. In mice, mutations at Nramp1 cause susceptibility to infection with phylogenically unrelated intracellular pathogens, including Mycobacterium bovis (bacille Calmette-Guérin (BCG))3 and Salmonella enterica serovar Typhimurium (Salmonella Typhimurium) (1, 2, 3, 4). In humans, polymorphic variants near or within the NRAMP1 gene are associated with differential susceptibility to tuberculosis and leprosy in areas of endemic diseases (5, 6, 7). Nramp1/Slc11a1 gene codes for a membrane phosphoglycoprotein formed of 12 transmembrane domains expressed in the lysosomal compartment of mononuclear phagocytes and in tertiary granules of neutrophils (8, 9). It functions as a pH-dependent divalent cation (e.g., Mn2+, Fe2+, and Zn2+) efflux pump at the phagosomal membrane (10), acting as a biological chelator for metals essential for intracellular replication of pathogens contained within phagosomes (10, 11). There are two Nramp1 allelic variants in mice that are associated with resistance (dominant, Nramp1G169) or susceptibility (recessive, Nramp1D169) to infections. The G169D mutant variant is unstable and is rapidly degraded in macrophages, and behaves as a complete loss-of-function (12). In permissive animals (Nramp1D169), infected i.v. with M. bovis (BCG), there is rapid bacterial replication in the spleen that peaks at 3 wk, followed by a curative phase associated with immune response, granuloma formation, and bacterial clearance. By contrast, there is little, if any, bacterial replication in the spleen and liver of resistant mice (Nramp1G169) during the same period (13).

In inbred mouse strains, there is a strict correlation between Nramp1 alleles and susceptibility (D169) and resistance (G169) to M. bovis (BCG) infection, with the notable exception of the BXH-2 strain. BXH-2 is a recombinant inbred strain derived from C57BL/6J (Nramp1D169) and C3H/HeJ (Nramp1G169) inbred strains (14) that is susceptible to M. bovis (BCG) infection despite being homozygote for C3H-derived resistance Nramp1G169 allele (3). The susceptibility phenotype of BXH-2 is variable with spleen bacterial counts 3 wk postinfection being 5- to 100-fold superior to those seen in the C3H/HeJ parent (3, 15). In addition, BXH-2 mice develop by 1 year of age a progressive and fatal myeloid leukemia by a two-step mutagenesis process, as follows: the first step is an inherited recessive mutation that causes early myeloproliferation of a Mac1+/GR1+ granulocyte precursor detectable within a few weeks after birth; the second late stage oncogenic event is by insertional mutagenesis of a replication-competent B-tropic ecotropic murine leukemia virus, which is itself generated by recombination between two integrated copies of N-tropic ecotropic murine leukemia virus designated Emv1 and Emv2 (16, 17, 18). We have previously shown that the first mutagenic event leading to myeloproliferation is inherited as a single recessive gene mapping to chromosome 8, and designated Myls. Homozygosity for the BXH-2 allele at the Myls locus results in abnormalities in spleen, lymph nodes, and bone marrow in the form of a massive infiltration of immature Mac1+/GR1+ granulocytes (19).

The minimal Myls interval was found to contain the Icsbp1 gene (also known as IRF-8) (15), a transcription factor member of the IFN regulatory factor (IRF) family expressed in B cells, T cells, and activated macrophages, and known to play a role in myeloid cell lineage differentiation (20). IRF family members are composed of an N-terminal DNA binding domain and a C-terminal IRF association domain (IAD). Icsbp1, like other IRF family members, acts as a transcriptional regulator that forms heterodimers to regulate expression of IFN-responsive genes through direct binding to IFN-stimulated response element (ISRE) sequences. Icsbp1 acts as a coactivator with IRF-1 to stimulate IFN-responsive gene expression, but acts as a corepressor with IRF-2 and negates IRF-1-mediated transcriptional activation. In association with lymphoid essential factor PU.1, Icsbp1 activates transcription of genes containing an Ets/IRF composite element, including IL-1, CD20, TLR-4, gp91phox, and macrophage scavenger receptor (for review, see Levi et al. (21)). In splenocytes, Icsbp1 expression can be induced by exposure to IFN-{gamma} and LPS (20).

We determined that BXH-2 mice carry a mutation (C915T) in the Icsbp1 gene, causing an arginine-to-cysteine substitution at position 294 (R294C) within the predicted IAD domain of the protein. Icsbp1R294C is responsible for the myeloproliferation of granulocyte precursors in BXH-2, but is also associated with reduced IFN-{gamma}-induced IL-12p40 expression by splenocytes in these mice (15). In a number of independent F2 crosses involving BXH-2 and several inbred strains, and segregating wild-type and mutant alleles for both Icsbp1 and Nramp1, we observed that Icsbp1 behaved as a modifier of Nramp1. Homozygosity for the mutant Icsbp1R294C allele caused increased bacterial replication in the spleen of F2 mice, with the effect being most obvious (5- to 8-fold increase) in resistant F2 animals homozygous (G169/G169) or heterozygous (G169/D169) for Nramp1 resistance alleles. The mutant Icsbp1R294C allele effect was completely recessive in agreement with a loss-of-activity of the Icsbp1R294C protein (15). Together, these results suggested that the loss-of-function Icsbp1R294C mutation has pleiotropic effects in BXH-2: it causes a chronic myeloid leukemia-like syndrome associated with myeloproliferation of granulocyte precursors, but also increases susceptibility to infection with an intracellular pathogen possibly associated with absence of IL-12p40 production by an affected myeloid compartment.

In this work, we have studied further the molecular basis for the loss-of-activity of the Icsbp1R294C protein isoform in BXH-2 mice. We found that Icsbp1R294C is a partial loss-of-function hypomorph allele displaying reduced protein expression level and transcriptional activity for an ISRE-containing target. This appears sufficient to cause absence of IL-12p40 protein production, and suggests a possible threshold effect in Icsbp1 function. This altered function is shown to cause a dramatic increase in susceptibility to Salmonella and Mycobacterium infections, linked to an inability to form granulomas in M. bovis (BCG)-infected organs. In addition, BXH-2 mice are found to be highly susceptible to malaria (Plasmodium chabaudi AS). Although mutant animals can control and clear the initial burst of blood parasitemia, they cannot mount immune response to the parasite, and are afflicted with cyclical waves of recurring parasitemia. These results highlight the critical role of Icsbp1 in both innate and acquired immunity to intracellular pathogens.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Animals

Inbred mouse strains C57BL/6J (B6), C3H/HeJ (C3H), A/J, and BALB/cJ mice were purchased from The Jackson Laboratory. A breeding stock of inbred strain BXH-2 obtained in the early 2000s from N. Jenkins and N. Copeland (National Cancer Institute, Frederick, MD) was subsequently expanded and maintained as a breeding colony at McGill University. BXH-2 males were used to generate F1 cross to BALB/cJ females. The F1 progeny were then crossed by brother/sister matings to produce F2 progeny, with no gender bias, that were phenotyped for susceptibility to Salmonella Typhimurium infection. F2 progeny were used between 2 and 6 mo of age. Maintenance and experimental manipulations of animals were performed according to the guidelines and regulations of the Canadian Council on Animal Care.

Genotyping

The allelic combination at the Nramp1, Tlr4, and Icsbp1 loci was determined in (BXH-2 x BALB/c)F2 mice by genotyping. Genomic DNA was prepared from tail biopsies by incubation in lysis buffer (100 mM Tris-HCl (pH 8.0), 5 mM EDTA (pH 8.0), 200 mM NaCl, and 0.2% SDS) containing 0.5 mg/ml proteinase K (55°C, 16 h), followed by phenol/chloroform extraction and precipitation with isopropanol (22). Primer pairs defining dinucleotide repeat markers D1Mcg2 (Nramp1) and D4Mcg24 (Tlr4) were previously described (23, 24). Sequence-length polymorphisms were genotyped by a standard PCR-based method using [{alpha}-32P]dATP labeling and separation on denaturing 9% polyacrylamide gels (22). A single-nucleotide polymorphism (C915T; Arg294Cys) was previously identified in exon 7 of the Icsbp/IRF-8 gene of BXH-2 (15). This sequence variant abolishes a HaeIII restriction enzyme site (5'-GGCC-3') in BXH-2, which can be scored by HaeIII digestion of a 397-bp exon 7 fragment generated by PCR amplification of genomic DNA using the oligonucleotide primer pair 5'-GCTCCCCATCTTCTAGGC-3' and 5'-ACCACCTCGTCCC GCTC-3', followed by separation on 2% agarose gel and visualization of ethidium bromide-stained products under UV.

Infection with Salmonella Typhimurium

BXH-2, BALB/cJ, A/J, C3H/HeJ, and (BALB/cJ x BXH-2)F2 animals were phenotyped for susceptibility to Salmonella Typhimurium infection, as we have previously described (25). One milliliter of a frozen culture of S. Typhimurium strain Keller (originally obtained from H. Robson, Royal Victoria Hospital, Montreal, Canada) was used to seed 100 ml of trypticase soy broth (OD600 nm of 0.1–0.2). Inocula were prepared by diluting the S. Typhimurium culture to concentrations of 0.5 x 104 to 1.0 x 104 CFU per 200 µl of PBS, and 0.2 ml of this suspension was used to infect mice by i.v. injection in the caudal tail vain. Survival of the animals was monitored several times per day, and moribund animals or animals showing obvious signs of distress were euthanized.

Infection with P. chabaudi AS

An lactate dehydrogenase virus-free isolate of P. chabaudi AS, originally obtained from D. Walliker (University of Edinburgh, Edinburgh, Scotland), was maintained by weekly passage in C57BL/6J mice by i.p. infection with 106 parasitized RBC (PRBC). For experimental infections, C57BL/6J, C3H/HeJ, and BXH-2 mice were infected i.p. with 106 PRBC suspended in 1 ml of pyrogen-free saline. Following infection (days 4–54), the percentage of PRBC was determined daily on duplicate thin blood smears stained with Dif-Quick (American Scientific Products), as described (26). Death was recorded daily, and moribund animals were sacrificed.

Infection with M. bovis (BCG)

M. bovis (BCG, strain Montreal) was passaged in vitro and prepared for in vivo infections, as we have previously described (2). Briefly, a single-cell suspension free of aggregates and containing 2 x 104 CFU in 0.2 ml of sterile PBS was used to inoculate mice by the i.v. route (caudal tail vein). At 1, 3, 5, and 8 wk postinfection, mice were euthanized and weighed, and the spleen and liver were removed aseptically. The extent of M. bovis (BCG) replication was determined by plating serial dilutions of spleen and liver homogenates on Dubos solid agar, and by counting the number of CFUs 21 days following incubation of plates at 37°C, as previously described (27).

In vitro production of IL-12 by splenocytes

C57BL/6J and BXH-2 mice were euthanized under anesthesia, and spleens were removed aseptically. Spleen cell suspensions were obtained by gently disrupting the tissue by passing through a 70-µm mesh in 3 ml of RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 50 µg/ml streptomycin (Invitrogen Life Technologies), 10 mM HEPES, and 5 mM 2-ME. Nucleated spleen cells were obtained following lysis of erythrocytes with hemolytic Gey’s solution, as previously described (28). Splenocytes were seeded in tissue culture vessels at 5 x 106 cells/ml, followed by incubation with given amounts of IFN-{gamma} and CpG (5'-TCCATGACGTTCCTGACGTT-3') for 24 h at 37°C. Tissue culture supernatants were collected and assayed for IL-12p40 production using a two-site sandwich ELISA method, as we have previously described (29).

RNA expression studies

Total cellular RNA was extracted from spleen and liver using a commercial reagent, and following the manufacturer recommended instructions (TRIzol; Invitrogen Life Technologies). Tissues were frozen on dry ice and homogenized by mechanical disruption using a Polytron (Brinkmann Instruments) in TRIzol reagent. The samples were incubated for 5 min at 20°C, followed by chloroform extraction. The aqueous phase was removed, and nucleic acids were precipitated with isopropanol. Pellets were washed with 75% ethanol and dissolved in RNase-free water treated with 0.1% diethylpyrocarbamate. For cDNA synthesis, total RNA (2 µg) was converted to cDNA in a 20 µl reaction containing 1 U of Moloney murine leukeumia virus reverse transcriptase (Invitrogen Life Technologies), dNTPs (500 µM each), and oligo(dT) primers (5 µM); First Strand Buffer; 10 mM DTT; and 1 µl of RNAGuard (Amersham), and the reaction was allowed to proceed for 50 min at 37°C. The reaction was inactivated by 15-min incubation at 70°C. Expression of individual genes was tested by standard PCR amplification of reverse-transcription products (RT-PCR) using total oligo(dT)-primed cDNA from spleen. The reaction mixture contained 0.5 µM each gene-specific oligo, 2 µl of cDNA (1/10 dilution), 10 µl of SYBR Green reaction mix (Invitrogen Life Technologies), and 1.25 mM MgCl2, and PCR was conducted in a LightCycler 2.0 System (Roche). PCR products were separated by agarose gel electrophoresis, stained with ethidium bromide (0.1% final), and photographed under UV (15).

Histology

Spleen and livers were harvested from C57BL/6J, C3H/HeJ, and BXH-2 animals infected with M. bovis (BCG) and were fixed in 4% buffered formaldehyde, embedded in paraffin, and sectioned, as we have previously described (19). Sections (5 µM) were stained with H&E for evaluation of pathologic changes, including appearance of granulomas.

Cytokine detection

Determination of 32 cytokines, chemokines, and growth factors in serum from experimental mice was conducted using RayBio Mouse Cytokine Ab Array II membranes (RayBiotech). Incubations, washes, and exposure to films were conducted, according to instructions from the manufacturer. Briefly, the arrays were blocked at 4°C overnight before being incubated (20°C for 2 h) with 700 µl (BCG infection) or 900 µl (P. chabaudi infection) of pooled mouse serum. The membranes were washed and incubated with biotin-conjugated primary Ab and HRP-conjugated streptavidin, according to the instructions of the manufacturer.

Plasmid construction

A 425-bp portion of the IL-12p40 gene promoter region containing ISRE and other regulatory sequences (30) was PCR amplified from C57BL/6J genomic DNA using oligonucleotide primers 5'-CCGCTCGAGTTCTTTGGGCCTGTAACACC-3' and 5'-GGAAGATCTACTGTTCCTTCTG CTGCCTT-3', followed by cloning into plasmid vector pGL3, which contains a luciferase reporter gene (Promega). A full-length cDNA corresponding to the mouse IRF-1 gene was modified by the in-frame addition of an antigenic cMyc epitope tag at the C terminus of the protein. Full-length mouse Icsbp1 cDNAs from C57BL/6J (wild type, Icsbp1R294) and from BXH-2/TyJ (Icsbp1C294) were modified by the in-frame addition of the antigenic HA epitope tag at the C terminus of the protein. Modified IRF-1 and Icsbp1 cDNAs were cloned into expression plasmid pcDNA3, which uses CMV promoter/enhancer sequences to drive high-level expression of recombinant cDNAs. Large-scale preparations of expression and reporter plasmids were obtained by banding on CsCl density gradients and used for transient transfection assays.

Cell culture, transfections, luciferase assays, and Western blots

RAW 264.7 (RAW) cells were maintained in DMEM (Sigma-Aldrich) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, and 50 µg/ml streptomycin (Invitrogen Life Technologies). RAW cells seeded in a 24-well tissue culture dish (1 x 105/well) were transfected using Lipofectamine PLUS (Invitrogen Life Technologies), with DNA mixtures consisting of 400 ng of luciferase pGL3 reporter construct with variable amounts of expression vectors (up to 100 ng), and according to an experimental protocol provided by the supplier of Lipofectamine reagent. pcDNA3 empty vector DNA was used to equalize all transfection reactions to the same amount of DNA. Twenty-four hours following transfection, cells were assayed for luciferase activity using the dual luciferase assay system (Promega). Whole cell extracts were separated on 8% SDS-polyacrylamide gel and transferred by electroblotting on 0.45-µm polyvinylidene difluoride membranes (Millipore). Similar loading of cell lysate and equal protein transfer to membrane were verified by staining with Ponceau S red (Sigma-Aldrich). The blots were incubated with mouse anti-HA mAb (1:500; Covance Research Products) in TBST (10 mM Tris-HCl (pH 8), 150 mM NaCl, 0.05% Tween 20) plus 5% skim milk (16 h at 4°C), followed by washing and incubation with a goat anti-mouse secondary Ab conjugated to HRP (1:20,000; Jackson ImmunoResearch Laboratories). Polyvinylidene difluoride membranes were stripped and incubated with the polyclonal goat anti-actin (I-19) Ab (1:1,000; Santa Cruz Biotecnology) in TBST plus 5% skim milk (16 h at 4°C), followed by washing and incubation with a donkey anti-goat secondary Ab-conjugated HRP (1:7,500; Santa Cruz Biotecnology). Chemiluminescence was used for the detection of immune complexes on the immunoblot (SuperSignal West Pico; Biolynx).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Transcriptional activity of the Icsbp1C294 isoform from BXH-2

Icsbp1/IRF-8 is a transcription factor that can heterodimerize with other IRF family members to either activate or repress expression of target genes bearing ISRE in their regulatory regions (21). It has been demonstrated that Icsbp1 can cooperate with IRF-1 to transcriptionally activate the IL-12p40 gene in RAW 264.7 macrophages (30). To assess the functional consequences of the R294C mutation in the IAD of Icsbp1 from BXH-2 (Fig. 1A) on protein function, we compared wild-type and mutant variants for their capacity to trans activate a reporter construct consisting of a 425-bp segment from the proximal promoter region of the IL-12p40 gene linked to luciferase (30). For this, RAW macrophages were transiently transfected with pcDNA3 expression vectors containing IRF-1 and one of either wild-type (Icsbp1R294) or mutant (Icsbp1C294) Icsbp1 variants, together with an IL-12p40-luciferase reporter construct. Luciferase activity was measured 24 h later. Results in Fig. 1, B and C, show that under these experimental conditions, trans activation of the IL-12p40 gene promoter in RAW cells requires exogenous Icsbp1 and IRF-1. The mean relative luciferase activity observed for Icsbp1R294-transfected cells was significantly higher than that seen for cells transfected with the Icsbp1C294 isoform (p ≤ 0.0015) with a ~50% reduction in trans activation potential of the R294C mutant (with independent DNA preparations, labeled 1 and 2). Additional dose-response experiments using increasing amounts of DNA encoding wild-type and mutant Icsbp1 in the transfection assay were conducted (Fig. 1C). These studies showed that for the same amount of DNA transfected into cells, the amount of protein transiently expressed for mutant Icsbp1C294 was clearly lower than for wild-type Icsbp1R294. Additionally, similar levels of luciferase activity were measured in cells transfected with either 50 ng of Icsbp1C294 plasmid or with 10 ng of Icsbp1R294 plasmid, and where the corresponding proteins were either readily detectable or undetectable, respectively (Fig. 1C). These results indicate that the R294C mutation constitutes a partial loss-of-function (hypomorph allele), affecting both transcriptional activity of Icsbp1 and protein expression, stability, or processing.


Figure 1
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 1. Transcriptional activition of the murine IL-12p40 promoter by IRF-1 in association with IcsbpR294 or IcsbpC294 protein isoforms. A, Schematic representation of the Icsbp1 protein showing the DNA binding domain, the IAD, and the position of the R294C mutation from BXH-2. B, RAW cells were transfected with expression plasmids containing IRF-1-cMyc (100 ng), a firefly luciferase reporter construct containing the IL-12p40 promoter (400 ng), a Renilla luciferase internal control (100 ng), and two different DNA preparations of pcDNA3 expression vectors containing either the wild-type IcsbpR294-HA or the BXH-2 mutant IcsbpC294-HA variant or the empty vector (100 ng). Luciferase activity was detected and quantified, as described in Materials and Methods. Each line represents the average of four transfected wells ± SD of the mean. C, RAW cells were transiently transfected with indicated amounts of pcDNA3 expression constructs containing either the wild-type IcsbpR294-HA or the BXH-2 mutant IcsbpC294-HA cDNAs, along with the IRF-1-cMyc construct (100 ng), the IL-12p40 reporter, and the Renilla luciferase internal control (see above). Each line represents the average of four transfected wells ± SD on the mean. Expression of wild-type and mutant HA-tagged Icsbp1 protein isoforms in transfected RAW macrophages was monitored by immunoblotting using a mouse anti-HA mAb. Actin expression was measured to ascertain similar protein loading on gel and similar transfer to blotting membrane.

 
The activity of the Icsbp1R294 and Icsbp1C294 variants was evaluated in vivo by monitoring production of IL-12p40 protein by C57BL/6J (B6) and BXH-2 splenocytes (15). Results in Fig. 2 show that although B6 splenocytes could readily produce IL-12p40 in response to stimulation by IFN-{gamma} and CpG, alone or in combination, BXH-2 spleen cells did not secrete detectable amounts of IL-12p40 in response to the same treatments. The attenuated transcriptional activity of Icsbp1C294 for the IL-12p40 gene promoter detected in transfected cells contrasts the complete absence of IL-12p40 protein production by Icsbp1C294 splenocytes from BXH-2. These findings indicate that although IcsbpC294 retains significant transcriptional activity, it behaves as a null mutation in vivo for IL-12p40 production. This suggests a complex threshold effect of the Icsbp1C294 hypomorph allele, resulting in extremely severe depletion of production of IL-12 and possibly other cytokines in BXH-2 mice.


Figure 2
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 2. Compromised IL-12p40 production in Icsbp1C294 splenocytes. Splenocytes harvested from B6 (Icsbp1R294) and BXH-2 (Icsbp1C294) mice were stimulated in vitro with various amounts of IFN-{gamma} and CpG, as indicated. Endogenous IL-12p40 production was measured by ELISA in culture supernatants 24 h after the induction. Each bar represents the average of two independent measurements.

 
Possible pleiotropic effects of the Icsbp1C294 mutation on innate and acquired immune defenses were therefore investigated in BXH-2 mice infected in vivo with intracellular pathogens.

Effect of Icsbp1R294C on host response to infection with M. bovis (BCG)

In a previous study, we have noted in a number of BXH-2-derived F2 mice infected with M. bovis (BCG) that homozygosity for the mutant Icsbp1C294 allele increased spleen bacterial load 3 wk after infection (15). The Icsbp1C294 allele effect was most visible in otherwise resistant F2 mice homozygote or heterozygote for the dominant protective Nramp1G169 allele. To explore further the effect of Icsbp1C294 on host defenses against M. bovis (BCG) infection, groups of C57BL/6J (permissive Nramp1D169, wild-type IcsbpR294), C3H/HeJ (nonpermissive Nramp1G169, wild-type IcsbpR294), and BXH-2 (nonpermissive Nramp1G169, mutant IcsbpC294) were infected i.v. with 2 x 104 M. bovis (BCG), and the extent of microbial replication was determined in the spleen and the liver at weeks 1, 3, 5, and 8 postinfection (Fig. 3). In resistant C3H controls, little, if any, bacterial replication was observed in the spleen over the course of the experiment (Fig. 3A). In contrast, there was active microbial replication in the spleen of C57BL/6J mice that peaked at 3 wk postinfection, followed by clearance of the bacterial load up to 8 wk; the differential growth of M. bovis (BCG) in the spleen of B6 and C3H mice is determined by Nramp1 alleles (Fig. 3A). By contrast, BXH-2 mice were permissive to M. bovis (BCG), despite a resistance Nramp1G169 allele, and were unable to control splenic bacterial replication, which continued for up to 8 wk postinfection (Fig. 3A). Likewise, although both C3H and B6 were able to clear the infection from liver over 8 wk, BXH-2 were unable to do so and displayed persistent infection in this organ (Fig. 3B). In addition and as expected from previous results (Figs. 1 and 2), C3H and B6 mice showed robust IL-12p40 production that was detectable in the serum at 3 wk postinfection and that persisted to 8 wk in B6 (Fig. 3D); however, there was no such IL-12p40 production in BXH-2 mice at any time postinfection (Fig. 3, C and D). These results indicate that the Icsbp1R294C mutation impairs innate (early) and acquired (late) immune response to mycobacterial infection in BXH-2.


Figure 3
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 3. Course of M. bovis (BCG) infection in C57BL/6J, C3H/HeJ, and BXH-2/TyJ mice. Groups of BXH-2 (resistant Nramp1G169; mutant IcsbpC294) and parental controls C57BL/6J (B6; susceptible Nramp1D169; wild-type IcsbpR294), and C3H/HeJ (C3H; resistant Nramp1G169; wild-type IcsbpR294) mice (n = 4–6) were injected i.v. with 2 x 104 M. bovis (BCG)/mouse (arrow), and the number of CFUs (logCFU ± SEM) was determined in spleen (A) and liver (B) at 1, 3, 5, and 8 wk postinfection. C, RNA was isolated from infected spleens, and expression of IL-12p40, IL-12p35, and beta-actin transcripts was monitored by RT-PCR and gel electrophoresis. D, Expression of IL-12p40 in serum of M. bovis (BCG)-infected B6, C3H, and BXH-2 mice (n = 4) was monitored using RayBio mouse array II membranes, as described in Materials and Methods.

 
The physiological basis for impaired response to M. bovis (BCG) infection was investigated. A key protective mechanism in host response to infection with mycobacteria is the formation of granulomas in infected tissues. These structures typically formed by the clustering of large phagocytic cells positive for acid fast bacilli surrounded by lymphocytes at the periphery limit the spread of mycobacterial infection (31). The effect of Icsbp1R294C mutation on the type and number of granulomas formed in response to M. bovis (BCG) infection was investigated in spleen (Fig. 4A) and liver (Fig. 4B) of C57BL/6J, C3H/HeJ, and BXH-2 at 3 and 8 wk postinfection. In C57BL/6J and C3H controls, there was a good correlation between the extent of bacterial replication and the number of granulomas formed. In B6 mice, transient bacterial replication associated with the susceptibility Nramp1D169 allele was concomitant to robust granulomatous response in both spleen and liver that peaked at 3 wk and persisted at 8 wk. In resistant C3H (Nramp1G169), low bacterial loads were paralleled by low numbers (spleen) or absence of detectable granulomas (liver) in infected organs. By contrast, in BXH-2 (Icsbp1C294) there was only a very modest granulomatous response in spleen and a complete absence of such response in liver at both 3 and 8 wk postinfection, despite continuing M. bovis (BCG) replication in these organs. Histological examination of granulomas formed in the three mouse strains revealed additional differences. Granulomas formed in BXH-2 tended to be of smaller size and less well organized than granulomas formed in C57BL/6J and C3H/HeJ controls, this difference being most obvious at the early 3-wk time point (Fig. 4, F–H).


Figure 4
View larger version (83K):
[in this window]
[in a new window]

  		FIGURE 4. Effect of Icsbp1R294C mutation on granuloma formation in M. bovis (BCG)-infected mice. Groups of BXH-2 (resistant Nramp1G169; mutant Icsbp1C294) and parental controls C57BL/6J (B6; susceptible, Nramp1D169; wild-type, Icsbp1R294), and C3H/HeJ (C3H; resistant, Nramp1G169; wild type, Icsbp1R294) mice were injected i.v. with 2 x 104 M. bovis (BCG), and the number of CFUs (logCFU ± SEM; Figure 4) and the number of granulomas (number per field at x200 magnification, 18 fields counted; {blacksquare}) were determined at 3 and 8 wk in spleen (A) and liver (B). Representative images of H & E-stained sections at x10 (C–E; I–K) and x400 original magnification (F–H; L–N). Granulomas are identified by arrows.

 
These results show that the IcsbpC294 mutation overrides the protective advantage that resistance alleles at Nramp1 provide against M. bovis (BCG) infection. They also indicate that failure to control mycobacterial replication in both the early and late phases of infection in BXH-2 is associated with inability to mount adequate granulomatous response in infected organs.

Effect of Icsbp1R294C on host response to infection with Salmonella Typhimurium

To further explore the relationship between Icsbp1 and Nramp1 in host resistance to intracellular pathogens, we tested the effect of the Icsbp1R294C mutation on the outcome of infection with Salmonella Typhimurium. In inbred mouse strains, two major loci, Nramp1 and Tlr4, are known to control Salmonella Typhimurium populations in the host, including extent of survival following acute infection (32). Mouse strains such as C57BL/6J and BALB/cJ harbor a Nramp1D169 susceptibility allele (recessive) and rapidly succumb to Salmonella Typhimurium infection, whereas strains such as A/J, DBA/2, 129S6/SvEvTac, and CBA/J that have a resistance Nramp1G169 allele (dominant) that restricts bacterial replication in liver and spleen can survive longer to the infection. In addition, C3H/HeJ mice carry a recessive mutation (P712H) in the Tlr4 gene that renders them susceptible to Salmonella Typhimurium infection, despite presence of a resistance Nramp1G169 allele (33, 34). BXH-2 mice (Icsbp1C294) harbor C3H/HeJ-derived resistance Nramp1G169 allele and susceptibility Tlr4H712 allele. Control experiments in Fig. 5A show that C57BL/6J (Nramp1D169), BALB/cJ (Nramp1D169), C3H/HeJ (Tlr4H712), and BXH-2 (Tlr4H712) are more susceptible to i.v. infection with Salmonella Typhimurium (1 x 103 CFU/mouse) and succumb within 7 days, whereas A/J survive up to 28 days following infection. To analyze a possible effect of the Icsbp1C294 mutation on resistance to Salmonella, an informative F2 cross in which the three loci segregate was produced between BXH-2 (mutant IcsbpC294, wild-type Nramp1G169, mutant Tlr4H712) and BALB/c (wild-type IcsbpR294, mutant Nramp1D169, wild-type Tlr4P712). (BALB/c x BXH-2)F2 mice were genotyped for Nramp1, Tlr4, and Icsbp1 (see Materials and Methods), and animals bearing at least one copy of wild-type dominant alleles for both Nramp1 and Tlr4 loci were selected and infected with 1 x 103 live Salmonella. The effect of wild-type (Icsbp1R294) or mutant (Icsbp1C294) alleles on survival to infection was evaluated (Fig. 5B). Homozygosity for mutant IcsbpC294 allele was associated with increased mortality in F2 mice, with a mean survival time (7.0 ± 1.2 days) similar to that of C3H/HeJ (7.0 ± 0 days), C57BL/6J (5 ± 0 days), and BALB/cJ (6 ± 0 days) susceptible controls (Fig. 5A). F2 mice heterozygous (Icsbp1R294/C294) or homozygous (Icsbp1R294/R294) for wild-type Icsbp1R294 showed significantly prolonged survival time compared with Icsbp1C294 mutant littermates (log rank test; p value 0.0002).


Figure 5
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 5. Effect of Icsbp1R294C mutation on survival of Salmonella Typhimurium-infected mice. A, Groups of BXH-2 (mutant IcsbpC294; resistant Nramp1G169; mutant TLR4H712), C57BL/6J (wild-type IcsbpR294; susceptible Nramp1D169; wild-type TLR4P712), C3H/HeJ (wild-type IcsbpR294; resistant Nramp1G169; mutant TLR4H715), BALB/cJ (wild-type IcsbpR294; susceptible Nramp1D169; wild-type TLR4P712), and A/J (wild-type IcsbpR294; resistant Nramp1G169; resistant TLR4P712) control mice were injected i.v. with 1 x 103 Salmonella Typhimurium, and survival was monitored during 28 days. B, (BALB/c x BXH-2)F2 mice bearing at least one wild-type (dominant) resistance allele for both TLR4 and Nramp1 loci were similarly infected, and survival is shown for subgroups of F2, according to their haplotype combination for wild-type (Icsbp1R294) or mutant (Icsbp1C294) alleles. The number of mice bearing each haplotype is indicated in parentheses (n).

 
These results show that the IcsbpC294 mutation can overcome the protective advantage that resistance alleles at Nramp1 and Tlr4 provide against acute infection with Salmonella Typhimurium.

Effect of Icsbp1R294C on host response to infection with the malarial parasite P.chabaudi AS

In the mouse, resistance to malaria requires an early inflammatory response to control the initial burst of intraerythrocytic parasite multiplication. This is dependent on sensing the presence and phagocytosis of parasitized erythrocytes and parasite products by spleen cells of the myeloid lineage, which quickly respond by producing proinflammatory cytokines such as IL-12, TNF-{alpha}, IFN-{gamma}, and IL-6. This response is progressively dampened by the counteraction of regulatory cytokines such as TGF-beta and IL-10, and this activity is essential for expression of adaptive immune mechanisms and for resolving the infection (35). We wished to examine the effect of the Icsbp1C294 mutation on coordinate expression of innate and adaptive immune mechanisms in a murine malaria model. The P. chabaudi AS model mimics the hematological stage of the disease, and the extent of blood-stage replication of the parasite can be used as a measure of susceptibility (36). In this model, permissive C3H/HeJ mice allow rapid replication of P. chabaudi, with peak parasitemia reaching ~50% at day 7 following i.p. infection with 1 x 106 PRBC (Fig. 6A). In contrast, resistant C57BL/6J mice sustain comparatively lower levels of blood parasitemia (~25% PRBC), which peaks later in infection (day 8–9). C3H/HeJ and C57BL/6J clear the infection by day 19, and do not sustain sequelae from the primary infection (Fig. 6A). In this model, BXH-2 mice displayed an intermediate level of parasitemia at the peak of infection (~40% PRBC), which was observed at day 8. Interestingly, following a recovery period, blood parasitemia rose again in BXH-2 mice in what appeared to be successive waves of parasitemia. Although detectable in averaged data from groups of BXH-2 (Fig. 6A), this unique recrudescence is most easily observed by examining parasitemia values from individual BXH-2 mice (Fig. 6B). Although several BXH-2 animals succumbed at or soon after the peak parasitemia, others completely recovered only to see parasitemia rise again to high levels (~50–60%). Up to three such asynchronous waves of recurring parasitemia could be seen during the 40-day observation period following recovery from the initial peak of infection (Fig. 6B). Recurrence of parasite replication in BXH-2 mice following recovery from initial bursts of parasitemia suggests that the Icsbp1C294 mutation impairs expression of long-term protective mechanisms against the malarial parasite.


Figure 6
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 6. Effect of Icsbp1R294C mutation on the course of infection with P. chabaudi AS. A, Groups of C57BL/6J (B6), C3H/HeJ (C3H), and BXH-2 female mice were injected i.p. with 1 x 106 P. chabaudi AS PRBC, and blood-stage replication of the parasite (% infected RBCs) was monitored between days 4 and 54 postinfection (Materials and Methods). Each point represents the mean of the number of PRBC per group of infected mice (n = 8) ± SEM. B, Course of blood stage parasitemia in eight individual female BXH-2 mice (each line represents a single mouse) showing recurrent waves of parasite replication. C, The expression of several cytokines and chemokines in serum of P. chabaudi AS-infected mice (pooled serum from three mice) was determined using RayBio mouse array II membranes (Materials and Methods). IL-12p40, p40 subunit of the cytokines IL-12 and IL-23; STNF RI, soluble receptor of TNF-{alpha}; TIMP-1, tissue inhibitor of metalloproteinases-1; TARC, thymus and activation-regulated chemokine.

 
To further probe the molecular basis for the loss of immunity against P. chabaudi AS in BXH-2, we compared cytokine/chemokine responses in sera of the three mouse strains in the early stages (days 2 and 5) of infection using commercially available cytokine Ab arrays (see Materials and Methods) (Fig. 6C). BXH-2 mice showed an overall depressed cytokine response early in the infection compared with resistant C57BL/6J and permissive C3H/HeJ controls. This was most obvious for IL-12p40, the soluble receptor of TNF-{alpha}, and to a lesser degree IFN-{gamma}, thymus and activation-regulated chemokine, tissue inhibitor of metalloproteinases-1, and MCP-1. These observations suggest a pleiotropic effect of the Icsbp1C294 mutation on the inflammatory cytokine response during malaria infection.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
We have previously shown that BXH-2 mice carry a mutation in the Icsbp1/IRF-8 gene (15). Homozygosity for this mutant allele has two major effects in vivo. It causes an expansion of the granulocytic compartment, which provides a replicative niche for a B-tropic ecotropic leukemia virus that generates clonal leukemic cells by insertional mutagenesis. It also appears to impair natural defenses against M. bovis (BCG) infection (15).

The Icsbp1R294C mutation found in BXH-2 maps in the IAD of the protein, a protein domain supporting heterodimerization of Icsbp1 with other IRF family members for activation or repression of target genes. R294 maps in a region of the IAD that has been studied in other IRF family members, including the close homologue IRF-4 (also known as Pip) (37). Multiple sequence alignments, secondary structure predictions, and mutagenesis experiments have been used to identify functionally important residues of the IAD of IRF-4. In IRF-4, {alpha}-helices at positions 300–314 and 325–335 bear a net positive charge that appears important for surface contacts between IRF-4 and its interacting partner PU.1. R294 in Icsbp1 corresponds to residue R333 in IRF-4, and thus maps within this helical domain. R333 has not been mutated in IRF-4, but conserved R328 within the same {alpha}-helix has been studied. The conservative mutation R328K was shown to decrease ternary complex formation with PU.1 and DNA binding by ~50%, whereas opposite nonconservative R328E and neutral R328Q substitutions completely disrupted ternary complex formation (38). An induced mutation at position 289 (R289E) in Icsbp1, corresponding to R328 in IRF-4, was previously shown to disrupt the interaction of Icsbp1 with IRF-2 and PU.1 (39). Together these results suggest that R294C affects a protein domain critical for interaction with other IRF family members, and a possible molecular basis for the reduced activity detected in this study for Icsbp1C294 in trans activation assay. However, we cannot formally exclude the possibility that it is not the loss of arginine at position 294, but rather the gain of a cysteine at this position that may underlie altered function of the Icsbp1C294 variant. The sulfhydril side chain of Cys294 may participate in novel intra- or intermolecular disulfide bridges that may alter either the structure of Icsbp1 or the stability of heterodimers formed with other transcriptional activators. Although such a mechanism is not compatible with the recessive behavior of the Icsbp1R294C allele, the characterization of additional mutations at R294 will be required to clarify this point.

Results in Fig. 1 show that the Icsbp1C294 is a functionally hypomorph allele with a pleiotropic effect on the Icsbp1 protein, which includes reduced protein stability/expressivity and reduced trans activation potential toward the IL-12p40 gene promoter. In contrast, when the ability of Icsbp1C294-expressing BXH-2 splenocytes to produce the IL-12p40 protein in response to IFN-{gamma} and CpG was tested ex vivo, the Icsbp1C294 variant behaved as a complete loss-of-function (Fig. 2). Several possibilities can be put forward to reconcile these two observations. The first is that the transcriptional activity of Icsbp1C294 measured in our assay may be overestimated, possibly due to the large amount of protein produced in transfected cells. Second, the mutation may have different effects on heterodimerization with multiple IRF proteins, and thus, different overall effects on transcriptional regulation of individual gene targets. Third, the hypomorph nature of Icsbp1C294 may have a threshold effect on myelopoiesis and IL-12 protein production. This situation would result in severe reduction of early production of type I cytokines in response to inflammatory or infectious stimuli. We favor the latter explanation because the phenotypic expression of the mutant Icsbp1C294 allele of BXH-2 in vivo, with respect to both myeloproliferation (19) and susceptibility to infection with M. bovis (BCG) (Fig. 3) or Toxoplasma gondii (40), is inherited as a fully recessive trait.

Previous studies in mice bearing a null mutation at Icsbp1 (Icsbp1–/–) have highlighted the role of Icsbp1 in host defenses against certain bacterial (41 , 42, 43), parasitic (44, 45), and viral infections (45, 46). In the present study, we used BXH-2 in additional, well-studied models of infection to explore the role of Icsbp1 in innate and acquired immune defenses. In the case of M. bovis (BCG), innate defenses play a critical role in controlling growth of M. bovis (BCG) in spleen and liver early during infection, and an intact Nramp1 protein is essential for macrophages to restrict intracellular replication during this period (47). In contrast, clearance of infection in Nramp1-defective permissive animals requires granuloma formation and robust T cell-mediated immune response in infected organs (13). In this study, we observe that Icsbp1 plays an important role in both phases. Early during infection (0–21 days), altered Icsbp1 function (Icsbp1C294) in BXH-2 overcomes the genetic advantage of a wild-type Nramp1G169 allele in these mice. Although BXH-2 mice show CFU counts at 3 wk lower than those seen in Nramp1-defective (Nramp1D169) C57BL/6J controls, they clearly support more replication than C3H controls that bear wild-type alleles at Nramp1 and Icsbp1 (Fig. 3). These results highlight the role of both genes in early response to mycobacterial infections. The effect of Icsbp1 mutation on Nramp1 could be explained in two mutually nonexclusive manners. First, Nramp1 transcription in phagocytes has been shown to be mediated by Icsbp1 in association with Miz-1- and PU.1-interacting partners, and Icsbp1–/– null mice express low levels of Nramp1 mRNA (48). However, Nramp1 expression was found similar in an in vitro experimental design using IFN-{gamma}- and CpG-induced peritoneal and splenic macrophage-enriched cell populations from C57BL/6J, C3H/HeJ, and BXH-2 strains, suggesting that the Icsbp1C294 mutation in BXH-2 does not seem to affect Nramp1 expression (data not shown). Second, reduced activity of Icbsp1C294 causes reduction of the type I cytokine IL-12 production, which is known to be critical to control mycobacterial infection (49). During the second, curative phase of the infection, BXH-2 mice apparently failed to mount an effective T cell-mediated immune response, with M. bovis (BCG) continuing to replicate in the spleen and liver for up to 8 wk postinfection. Strikingly, continuous microbial replication in BXH-2 was associated with the inability to form granulomas in infected organs, compared with C57BL/6J mice that have a bacterial load at 3 wk superior to BXH-2, but that can nevertheless clear the infection by 8 wk (Figs. 3 and 4). Lack of granulomatous response in infected BXH-2 was linked to absence of type I cytokine production in the serum, most notably IL-12p40 (Fig. 3). IL-12 was previously shown to be essential in host response to mycobacteria in mice (49, 50, 51) and in human patients (5). IL-12p40 gene codes for the p40 subunit of the cytokines IL-12 and IL-23, which are both known to be major inducers of IFN-{gamma} production by T and NK cells. IFN-{gamma} induces macrophages to activate their bactericidal activities, among which the production of NO, and consequently the destruction of the bacilli, as previously illustrated in IL-12p40 and IFN-{gamma} mutant mice. Indeed, defective granuloma formation has been previously reported in IL-12p40–/– (49) and in IFN-{gamma}–/– mutant mice (52) infected with avirulent (M. bovis BCG) or virulent mycobacteria (M. tuberculosis) (50). Taken together, these results highlight the importance of Icsbp1 in orchestrating innate and acquired immune responses during mycobacterial infection. They also raise the possibility that mutations in ICSBP1 may be associated with rare, but severe mycobacteriosis in humans.

Innate resistance to infection with another intracellular pathogen, S. Typhimurium, requires intact Nramp1 and Tlr4 function, and elimination of either genes in inbred mouse strains BALB/c (Nramp1D169; impaired macrophage microbicidal function) and C3H/HeJ (Tlr4H712; impaired macrophage activation and lack of Th1 effector response) causes susceptibility, as measured by increased mortality following acute infection (32). In this study, we observed (Fig. 5) that impaired Icsbp1 function in Icsbp1C294/C294 homozygotes significantly reduced survival times in (BALB/c x BXH-2)F2 bearing functional allelic combinations at Nramp1 and Tlr4. Again, the effect could be explained in part by reduced expression of protective type I cytokines, including IL-12 (53), or more directly through reduced transcriptional activity of the Icsbp1C294 protein isoform. Indeed, the promoter of the Tlr4 gene contains a composite IFN response factor/Ets motif bound by PU.1 and Icsbp1 (54).

Finally, we observed that BXH-2 mice show an increased susceptibility to malaria in a blood-stage model caused by P. chabaudi AS. In this model, early inflammatory response during rising parasitemia is protective and requires secretion of Th1 cytokines IL-12, IFN-{gamma}, IL-6, and TNF-{alpha} by spleen cells of the myeloid lineage, including macrophages, dendritic cells, and NK cells. This inflammatory response is progressively dampened by expression of regulatory cytokines TGF-beta/IL-10, and the balance between the two responses is critical. Clearance of the infection and long-term protection requires both T cell- and B cell-mediated immune responses (35). In this study, we observed increased blood parasitemia at the peak of infection in Icsbp1-deficient BXH-2 mice (Fig. 6), which was concomitant to reduced expression of IL-12p40 and IFN-{gamma} early during infection. This is in agreement with published data showing that deletion of the IL-12p40 gene causes increased parasitemia at the peak of Plasmodium infection (55, 56). Macrophages from IL-12p40–/– mice were shown to secrete higher levels of TGF-beta, which down-regulates NO and consequently restricts their ability to kill intracellular parasites (57). Therefore, Icsbp1 function is required for early control of blood-stage replication of the malarial parasite.

In BXH-2, we further observed waves of recurrent parasitemia in animals surviving the initial burst of blood-stage parasite replication. In individual mice, we noted up to three waves of recurring parasitemia, suggesting that although BXH-2 mice can respond and eliminate bursts of parasitemia, impaired Icsbp1 function results in failure to mount adequate memory response to prevent their recurrence. Waves of recurring parasitemia could emerge from small remaining numbers of infected RBCs (incomplete clearance of infection), or from replication of parasites sheltered in reticuloendothelial organs. The parasite could also be able to switch antigenic variants, and take advantage of a delayed elimination by the immune system impaired due to absence of IL-12 and IFN-{gamma}. Similar waves of recurring Plasmodium parasitemia have been observed in IL-12p40–/– mice (55, 56), and this has been attributed to lower levels of Th1-dependent IgG2a and IgG3 and higher level of Th2-dependent IgG1 than wild-type mice during the infection (55). Likewise, mice defective in GM-CSF show recrudescent parasitemia following malaria infection; in this case, the impaired host response has been associated with reduced numbers of mature macrophages in these mutants (58).

Together, our studies in BXH-2 mice clearly demonstrate that Icsbp1 plays a key role in early innate host response to a range of bacterial and parasitic pathogens. Furthermore, they show that intact Icsbp1 is required for the development of long-term protective immune responses. The pleiotropic effect of Icsbp1C294 on host defenses is best explained by a threshold effect of a hypomorph allele on IL-12 production. These results raise the possibility that parallel mutations in the ICSBP1 gene may be associated with mycobacterial infections in humans. In particular, we suggest that ICSBP1 may be a good candidate for two human conditions, as follows: 1) the so-called "BCG-osis" observed in patients developing disseminated infection following BCG vaccination, and 2) the Mendelian susceptibility to mycobacterial diseases (MSMD), which is a broader syndrome that involves infection with weakly virulent mycobacterial species (including environmental mycobacteria), with occasional concomitant infection with nontyphoidal or typhoidal species of Salmonella. Previous studies of MSMD patients have identified independent mutations in the IFN-{gamma}R1, STAT1, and NF-{kappa}B essential modulator (I{kappa}beta kinase {gamma}), and interestingly in the IL-12 p40 and IL-12 Rbeta1 genes (59, 60). The unique infection susceptibility phenotype of BXH-2 mice reported in this study for M. bovis (BCG) and Salmonella, together with the noted absence of IL-12p40 production by BXH-2 phenotype, identify ICSBP1 as a strong candidate for MSMD.


   Acknowledgments
 
We thank Dr. Jerry Pelletier (McGill University) for helpful discussions during this work, Dr. Mariela Segura (McGill University) for help with cytokine assays, Rosalie Wilkinson for technical assistance, and Dr. Anny Fortin (Emerillon Therapeutics) for critical reading of this manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by research grants to P.G. from Canadian Genetic Diseases Network and the Cancer Research Society. P.G. is a James McGill Professor of Biochemistry. K.T. was supported by studentships from the Canadian Institutes of Health Research and the Ruth and Alex Dworkin Scholarship from the McGill Faculty of Medicine. D.M. is a McGill William Dawson Scholar of Human Genetics. Back

2 Address correspondence and reprint requests to Dr. Philippe Gros, Department of Biochemistry, 3655 Sir William Osler Promenade, Room 907, Montreal, Quebec, Canada, H3G-1Y6. E-mail address: philippe.gros{at}mcgill.ca Back

3 Abbreviations used in this paper: BCG, bacille Calmette-Guérin; HA, hemagglutinin; IAD, IRF association domain; IRF, IFN regulatory factor; ISRE, IFN-stimulated response element; MSMD, Mendelian susceptibility to mycobacterial diseases; PRBC, parasitized RBC. Back

Received for publication September 18, 2006. Accepted for publication June 18, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Skamene, E., E. Schurr, P. Gros. 1998. Infection genomics: Nramp1 as a major determinant of natural resistance to intracellular infections. Annu. Rev. Med. 49: 275-287. [Medline]
  2. Gros, P., E. Skamene, A. Forget. 1981. Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J. Immunol. 127: 2417-2421. [Abstract]
  3. Skamene, E., P. Gros, A. Forget, P. A. Kongshavn, C. St. Charles, B. A. Taylor. 1982. Genetic regulation of resistance to intracellular pathogens. Nature 297: 506-509. [Medline]
  4. Plant, J., A. A. Glynn. 1979. Locating Salmonella resistance gene on mouse chromosome 1. Clin. Exp. Immunol. 37: 1-6. [Medline]
  5. Casanova, J. L., L. Abel. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20: 581-620. [Medline]
  6. Bellamy, R.. 2003. Susceptibility to mycobacterial infections: the importance of host genetics. Genes Immun. 4: 4-11. [Medline]
  7. Malik, S., L. Abel, H. Tooker, A. Poon, L. Simkin, M. Girard, G. J. Adams, J. R. Starke, K. C. Smith, E. A. Graviss, et al 2005. Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease. Proc. Natl. Acad. Sci. USA 102: 12183-12188. [Abstract/Free Full Text]
  8. Canonne-Hergaux, F., J. Calafat, E. Richer, M. Cellier, S. Grinstein, N. Borregaard, P. Gros. 2002. Expression and subcellular localization of NRAMP1 in human neutrophil granules. Blood 100: 268-275. [Abstract/Free Full Text]
  9. Gruenheid, S., E. Pinner, M. Desjardins, P. Gros. 1997. Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. J. Exp. Med. 185: 717-730. [Abstract/Free Full Text]
  10. Jabado, N., A. Jankowski, S. Dougaparsad, V. Picard, S. Grinstein, P. Gros. 2000. Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH-dependent manganese transporter at the phagosomal membrane. J. Exp. Med. 192: 1237-1248. [Abstract/Free Full Text]
  11. Gros, P., E. Schurr. 2002. Immunogenetics of host response to bacteria in mice. S. H. E. Kaufman, and A. Sher, and R. Ahmed, eds. Immunology of Infectious Diseases 407-419. ASM Press,
  12. Malo, D., K. Vogan, S. Vidal, J. Hu, M. Cellier, E. Schurr, A. Fuks, N. Bumstead, K. Morgan, P. Gros. 1994. Haplotype mapping and sequence analysis of the mouse Nramp gene predict susceptibility to infection with intracellular parasites. Genomics 23: 51-61. [Medline]
  13. Pelletier, M., A. Forget, D. Bourassa, P. Gros, E. Skamene. 1982. Immunopathology of BCG infection in genetically resistant and susceptible mouse strains. J. Immunol. 129: 2179-2185. [Abstract]
  14. Taylor, B. A.. 1978. Recombinant inbred strains: use in gene mapping. H. C. M. , III, ed. Origins of Inbred Mice 423-438. Academic Press, New York.
  15. Turcotte, K., S. Gauthier, A. Tuite, A. Mullick, D. Malo, P. Gros. 2005. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J. Exp. Med. 201: 881-890. [Abstract/Free Full Text]
  16. King, S. R., B. J. Berson, R. Risser. 1988. Mechanism of interaction between endogenous ecotropic murine leukemia viruses in (BALB/c x C57BL/6) hybrid cells. Virology 162: 1-11. [Medline]
  17. Bedigian, H. G., D. A. Johnson, N. A. Jenkins, N. G. Copeland, R. Evans. 1984. Spontaneous and induced leukemias of myeloid origin in recombinant inbred BXH mice. J. Virol. 51: 586-594. [Abstract/Free Full Text]
  18. Bedigian, H. G., L. A. Shepel, P. C. Hoppe. 1993. Transplacental transmission of a leukemogenic murine leukemia virus. J. Virol. 67: 6105-6109. [Abstract/Free Full Text]
  19. Turcotte, K., S. Gauthier, L. M. Mitsos, C. Shustik, N. G. Copeland, N. A. Jenkins, J. C. Fournet, P. Jolicoeur, P. Gros. 2004. Genetic control of myeloproliferation in BXH-2 mice. Blood 103: 2343-2350. [Abstract/Free Full Text]
  20. Tamura, T., K. Ozato. 2002. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J. Interferon Cytokine Res. 22: 145-152. [Medline]
  21. Levi, B. Z., S. Hashmueli, M. Gleit-Kielmanowicz, A. Azriel, D. Meraro. 2002. ICSBP/IRF-8 transactivation: a tale of protein-protein interaction. J. Interferon Cytokine Res. 22: 153-160. [Medline]
  22. Mitsos, L. M., L. R. Cardon, A. Fortin, L. Ryan, R. LaCourse, R. J. North, P. Gros. 2000. Genetic control of susceptibility to infection with Mycobacterium tuberculosis in mice. Genes Immun. 1: 467-477. [Medline]
  23. Malo, D., S. M. Vidal, J. Hu, E. Skamene, P. Gros. 1993. High-resolution linkage map in the vicinity of the host resistance locus Bcg. Genomics 16: 655-663. [Medline]
  24. Qureshi, S. T., L. Lariviere, G. Sebastiani, S. Clermont, E. Skamene, P. Gros, D. Malo. 1996. A high-resolution map in the chromosomal region surrounding the Lps locus. Genomics 31: 283-294. [Medline]
  25. Sebastiani, G., V. Blais, V. Sancho, S. N. Vogel, M. M. Stevenson, P. Gros, J. M. Lapointe, S. Rivest, D. Malo. 2002. Host immune response to Salmonella enterica serovar Typhimurium infection in mice derived from wild strains. Infect. Immun. 70: 1997-2009. [Abstract/Free Full Text]
  26. Fortin, A., L. R. Cardon, M. Tam, E. Skamene, M. M. Stevenson, P. Gros. 2001. Identification of a new malaria susceptibility locus (Char4) in recombinant congenic strains of mice. Proc. Natl. Acad. Sci. USA 98: 10793-10798. [Abstract/Free Full Text]
  27. Forget, A., E. Skamene, P. Gros, A. C. Miailhe, R. Turcotte. 1981. Differences in response among inbred mouse strains to infection with small doses of Mycobacterium bovis BCG. Infect. Immun. 32: 42-47. [Abstract/Free Full Text]
  28. Hanna, Z., D. G. Kay, N. Rebai, A. Guimond, S. Jothy, P. Jolicoeur. 1998. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95: 163-175. [Medline]
  29. Sam, H., M. M. Stevenson. 1999. In vivo IL-12 production and IL-12 receptors beta1 and beta2 mRNA expression in the spleen are differentially up-regulated in resistant B6 and susceptible A/J mice during early blood-stage Plasmodium chabaudi AS malaria. J. Immunol. 162: 1582-1589. [Abstract/Free Full Text]
  30. Masumi, A., S. Tamaoki, I. M. Wang, K. Ozato, K. Komuro. 2002. IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages. FEBS Lett. 531: 348-353. [Medline]
  31. Smith, I.. 2003. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 16: 463-496. [Abstract/Free Full Text]
  32. Roy, M. F., D. Malo. 2002. Genetic regulation of host responses to Salmonella infection in mice. Genes Immun. 3: 381-393. [Medline]
  33. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088. [Abstract/Free Full Text]
  34. Qureshi, S. T., L. Lariviere, G. Leveque, S. Clermont, K. J. Moore, P. Gros, D. Malo. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189: 615-625. [Abstract/Free Full Text]
  35. Stevenson, M. M., E. M. Riley. 2004. Innate immunity to malaria. Nat. Rev. Immunol. 4: 169-180. [Medline]
  36. Fortin, A., M. M. Stevenson, P. Gros. 2002. Complex genetic control of susceptibility to malaria in mice. Genes Immun. 3: 177-186. [Medline]
  37. Nguyen, H., J. Hiscott, P. M. Pitha. 1997. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 8: 293-312. [Medline]
  38. Ortiz, M. A., J. Light, R. A. Maki, N. Assa-Munt. 1999. Mutation analysis of the Pip interaction domain reveals critical residues for protein-protein interactions. Proc. Natl. Acad. Sci. USA 96: 2740-2745. [Abstract/Free Full Text]
  39. Tsujimura, H., T. Tamura, C. Gongora, J. Aliberti, C. Reis e Sousa, A. Sher, K. Ozato. 2003. ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro. Blood 101: 961-969. [Abstract/Free Full Text]
  40. Trischmann, T. M.. 1984. Single locus in BXH-2 mice responsible for inability to control early proliferation of Trypanosoma cruzi. Infect. Immun. 46: 658-662. [Abstract/Free Full Text]
  41. Fehr, T., G. Schoedon, B. Odermatt, T. Holtschke, M. Schneemann, M. F. Bachmann, T. W. Mak, I. Horak, R. M. Zinkernagel. 1997. Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. J. Exp. Med. 185: 921-931. [Medline]
  42. Hein, J., V. A. Kempf, J. Diebold, N. Bucheler, S. Preger, I. Horak, A. Sing, U. Kramer, I. B. Autenrieth. 2000. Interferon consensus sequence binding protein confers resistance against Yersinia enterocolitica. Infect. Immun. 68: 1408-1417. [Abstract/Free Full Text]
  43. Ko, J., A. Gendron-Fitzpatrick, G. A. Splitter. 2002. Susceptibility of IFN regulatory factor-1 and IFN consensus sequence binding protein-deficient mice to brucellosis. J. Immunol. 168: 2433-2440. [Abstract/Free Full Text]
  44. Scharton-Kersten, T., C. Contursi, A. Masumi, A. Sher, K. Ozato. 1997. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J. Exp. Med. 186: 1523-1534. [Abstract/Free Full Text]
  45. Giese, N. A., L. Gabriele, T. M. Doherty, D. M. Klinman, L. Tadesse-Heath, C. Contursi, S. L. Epstein, H. C. Morse, III. 1997. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J. Exp. Med. 186: 1535-1546. [Abstract/Free Full Text]
  46. Holtschke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobeloch, L. Gabriele, J. F. Waring, et al 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87: 307-317. [Medline]
  47. Lam-Yuk-Tseung, S., P. Gros. 2003. Genetic control of susceptibility to bacterial infections in mouse models. Cell Microbiol. 5: 299-313. [Medline]
  48. Alter-Koltunoff, M., S. Ehrlich, N. Dror, A. Azriel, M. Eilers, H. Hauser, H. Bowen, C. H. Barton, T. Tamura, K. Ozato, B. Z. Levi. 2003. Nramp1-mediated innate resistance to intraphagosomal pathogens is regulated by IRF-8, PU.1, and Miz-1. J. Biol. Chem. 278: 44025-44032. [Abstract/Free Full Text]
  49. Cooper, A. M., J. Magram, J. Ferrante, I. M. Orme. 1997. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186: 39-45. [Abstract/Free Full Text]
  50. Wakeham, J., J. Wang, J. Magram, K. Croitoru, R. Harkness, P. Dunn, A. Zganiacz, Z. Xing. 1998. Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis bacille Calmette-Guerin in IL-12-deficient mice. J. Immunol. 160: 6101-6111. [Abstract/Free Full Text]
  51. Cooper, A. M., A. Kipnis, J. Turner, J. Magram, J. Ferrante, I. M. Orme. 2002. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol. 168: 1322-1327. [Abstract/Free Full Text]
  52. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, B. R. Bloom. 1993. An essential role for interferon {gamma} in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178: 2249-2254. [Abstract/Free Full Text]
  53. De Jong, R., F. Altare, I. A. Haagen, D. G. Elferink, T. Boer, P. J. van Breda Vriesman, P. J. Kabel, J. M. Draaisma, J. T. van Dissel, F. P. Kroon, et al 1998. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280: 1435-1438. [Abstract/Free Full Text]
  54. Rehli, M., A. Poltorak, L. Schwarzfischer, S. W. Krause, R. Andreesen, B. Beutler. 2000. PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J. Biol. Chem. 275: 9773-9781. [Abstract/Free Full Text]
  55. Su, Z., M. M. Stevenson. 2002. IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. J. Immunol. 168: 1348-1355. [Abstract/Free Full Text]
  56. Bastos, K. R., R. Barboza, R. M. Elias, L. R. Sardinha, M. G. Grisotto, C. R. Marinho, G. P. Amarante-Mendes, J. M. Alvarez, M. R. Lima. 2002. Impaired macrophage responses may contribute to exacerbation of blood-stage Plasmodium chabaudi chabaudi malaria in interleukin-12-deficient mice. J. Interferon Cytokine Res. 22: 1191-1199. [Medline]
  57. Bastos, K. R., J. M. Alvarez, C. R. Marinho, L. V. Rizzo, M. R. Lima. 2002. Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J. Leukocyte Biol. 71: 271-278. [Abstract/Free Full Text]
  58. Riopel, J., M. Tam, K. Mohan, M. W. Marino, M. M. Stevenson. 2001. Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria. Infect. Immun. 69: 129-136. [Abstract/Free Full Text]
  59. Casanova, J. L., L. Abel. 2004. The human model: a genetic dissection of immunity to infection in natural conditions. Nat. Rev. Immunol. 4: 55-66. [Medline]
  60. Casanova, J. L., L. Abel. 2007. Human genetics of infectious diseases: a unified theory. EMBO J. 26: 915-922. [Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. F. Brereton, C. E. Sutton, S. J. Lalor, E. C. Lavelle, and K. H. G. Mills
Inhibition of ERK MAPK Suppresses IL-23- and IL-1-Driven IL-17 Production and Attenuates Autoimmune Disease
J. Immunol., August 1, 2009; 183(3): 1715 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J.-F. Marquis, R. LaCourse, L. Ryan, R. J. North, and P. Gros
Disseminated and Rapidly Fatal Tuberculosis in Mice Bearing a Defective Allele at IFN Regulatory Factor 8
J. Immunol., March 1, 2009; 182(5): 3008 - 3015.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
F. B. Hickey, C. F. Brereton, and K. H. G. Mills
Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells
J. Leukoc. Biol., July 1, 2008; 84(1): 234 - 243.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Alter-Koltunoff, S. Goren, J. Nousbeck, C. G. Feng, A. Sher, K. Ozato, A. Azriel, and B.-Z. Levi
Innate Immunity to Intraphagosomal Pathogens Is Mediated by Interferon Regulatory Factor 8 (IRF-8) That Stimulates the Expression of Macrophage-specific Nramp1 through Antagonizing Repression by c-Myc
J. Biol. Chem., February 1, 2008; 283(5): 2724 - 2733.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turcotte, K.
Right arrow Articles by Gros, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turcotte, K.
Right arrow Articles by Gros, P.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Malaria
*Salmonella Infections
*Tuberculosis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS